Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial
Stéphane de Botton(Université Paris-Saclay), for the European Apl Group, Consuelo Rayón(European Union), Pierre Fenaux(Saint Louis University Hospital), Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), Claude Preudhomme(Centre Hospitalier Universitaire de Lille), Christine Chomienne(Inserm), Éric Deconinck(European Union), Jesús F. San Miguel(Clinica Universidad de Navarra), Éric Solary(Inserm), B Desablens(European Union), H. Link(European Union), U Hess(Université Paris Cité), Frédéric Maloisel(European Union), Philippe Travade(European Union), Katherine M. Geiser(University of Bern), Sylvie Chevret(Saint Louis University Hospital), Pascale Cony Makhoul(European Union), Claude Gardin(Sorbonne Université), Aspasia Stamatoullas(European Union), Nathalie Fegueux(European Union), Xavier Thomas(Hôpital Lyon Sud), Dominique Bordessoule(Centre Hospitalier Universitaire de Limoges), Laurent Degos(Inserm), Sylvie Castaigné(Hôpital André Mignot), Martin F. Fey(European Union), Jean‐Jacques Sotto(European Union), Hervé Dombret(University of London Institute in Paris), Agnès Guerci(Centre Hospitalier Régional et Universitaire de Nancy), Françoise Huguet(Centre Hospitalier Universitaire de Toulouse)
Cited by 145
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k